Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Esperion Therapeutics Inc shares valued at $7,866 were sold by Halladay Benjamin on Dec 17 ’24. At $2.42 per share, Halladay Benjamin sold 3,245 shares. The insider’s holdings dropped to 240,691 shares worth approximately $0.55 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Warren Eric sold 2,234 shares, netting a total of over 5,426 in proceeds. Following the sale of shares at $2.43 each, the insider now holds 160,121 shares.
Before that, Koenig Sheldon L. had sold 12,447 shares from its account. In a trade valued at $30,694, the President and CEO traded Esperion Therapeutics Inc shares for $2.47 each. Upon closing the transaction, the insider’s holdings decreased to 12,447 shares, worth approximately $1.7 million.
As published in their initiating research note from Goldman on December 18, 2024, Esperion Therapeutics Inc [ESPR] has been a Neutral and the price target has been revised to $4. Analysts at Cantor Fitzgerald started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of June 20, 2024, BofA Securities has decreased its “Neutral” rating to a “an Underperform” for ESPR. Earlier on January 03, 2024, BofA Securities downgraded its rating. Their new recommendation was “a Neutral” for ESPR stock which previously was a “a Buy”.
Analyzing ESPR Stock Performance
During the last five days, there has been a drop of approximately -6.50%. Over the course of the year, Esperion Therapeutics Inc shares have dropped approximately -23.08%. Shares of the company reached a 52-week high of $3.94 on 12/09/24 and a 52-week low of $1.58 on 10/02/24. A 50-day SMA is recorded $2.42, while a 200-day SMA reached $2.24. Nevertheless, trading volume fell to 1.96 million shares from 2.79 million shares the previous day.
Support And Resistance Levels for Esperion Therapeutics Inc (ESPR)
According to the 24-hour chart, there is a support level at 2.22, which, if violated, would cause prices to drop to 2.14. In the upper region, resistance lies at 2.34. The next price resistance is at 2.38. RSI (Relative Strength Index) is 44.78 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.40, which suggests the price will decrease in the coming days. Percent R is at 78.10%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
